Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.62 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.61 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.61 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.61 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.61 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.61 |
| ▸ | BLM | P54132 | 3/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.55 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.55 |
| ▸ | THRB | P10828 | 2/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | MTOR | P42345 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7274518 | 1.00 | LMNA (0.62) | LMNACYP2D6CYP2C9HSD17B10CHRM2 | |
| SCHEMBL198083 | 1.00 | LMNA (0.62) | LMNACYP2D6CYP2C9HSD17B10CHRM2 | |
| Hydrochloric Acid SCHEMBL7268076 | 0.98 | LMNA (0.61) | LMNACYP2D6CYP2C9HSD17B10CHRM2 | |
| SCHEMBL3916189 | 0.98 | LMNA (0.64) | LMNACYP2D6CYP2C9HSD17B10CHRM2 | |
| SCHEMBL2062723 | 0.98 | LMNA (0.64) | LMNACYP2D6CYP2C9HSD17B10CHRM2 | |
| SCHEMBL415802 | 0.98 | LMNA (0.64) | LMNACYP2D6CYP2C9HSD17B10CHRM2 | |
| Hydrochloric Acid SCHEMBL8987487 | 0.97 | LMNA (0.59) | LMNACYP2D6CYP2C9HSD17B10CHRM2 | |
| Iodide SCHEMBL16713395 | 0.97 | LMNA (0.62) | LMNACYP2D6CYP2C9HSD17B10CHRM2 | |
| Hydrochloric Acid SCHEMBL7269400 | 0.97 | LMNA (0.62) | LMNACYP2D6CYP2C9HSD17B10CHRM2 | |
| SCHEMBL19105458 | 0.85 | CYP2D6 (0.51) | LMNACYP2D6CYP2C9HSD17B10CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130316409-A1 | Nitrilases, Nucleic Acids Encoding Them and Methods for Making and Using Them | VERENIUM CORPORATION (US) | 2013-11-28 | — | — | US | claimed |
| US-8501451-B2 | Nitrilases and methods for making and using them | VERENIUM CORPORATION (US) | 2013-08-06 | — | — | US | claimed |
| US-20120009637-A1 | Nitrilases, Nucleic Acids Encoding Them and Methods For Making and Using Them | VERENIUM CORPORATION (US) | 2012-01-12 | — | — | US | claimed |
| US-20120009633-A1 | NITRILASES AND METHODS FOR MAKING AND USING THEM | VERENIUM CORPORATION (US) | 2012-01-12 | — | — | US | claimed |
| US-8088613-B2 | Nitrilases, nucleic acids encoding them and methods for making and using them | VERENIUM CORPORATION (US) | 2012-01-03 | — | — | US | claimed |
| US-8034595-B2 | Nitrilases and methods for making and using them | VERENIUM CORPORATION (US) | 2011-10-11 | — | — | US | claimed |
| US-20090162906-A1 | Biocatalysts; mutant and/or chemically modified enzymes; stereoselectively hydrolyze an amino nitrile or cyanohydrin intermediate to produce the corresponding carboxylic acid; e.g. phenylglycinonitrile from benzaldehyde, potassium cyanide and ammonium chloride | VERENIUM CORPORATION (US) | 2009-06-25 | — | — | US | claimed |
| US-7300775-B2 | Methods for producing α-substituted carboxylic acids using nitrilases and strecker reagents | VERENIUM CORPORATION (US) | 2007-11-27 | — | — | US | claimed |
| EP-1242589-A2 | METHODS FOR PRODUCING ENANTIOMERICALLY PURE ALPHA-SUBSTITUTED CARBOXYLIC ACIDS | DIVERSA CORPORATION (US) | 2002-09-25 | — | — | EP | claimed |
| US-20020012974-A1 | Genetic engineered nucleic acid promoter | VERENIUM CORPORATION | 2002-01-31 | — | — | US | claimed |
| WO-2001048175-A2 | METHODS FOR PRODUCING ENANTIOMERICALLY PURE α-SUBSTITUTED CARBOXYLIC ACIDS | DIVERSA CORPORATION (US) | 2001-07-05 | — | — | WO | claimed |
| US-9828594-B2 | Nitrilases, nucleic acids encoding them and methods for making and using them | BASF ENZYMES LLC (US) | 2017-11-28 | — | — | US | disclosed |
| US-20160355801-A1 | NITRILASES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM | VERENIUM CORPORATION | 2016-12-08 | — | — | US | disclosed |
| US-9315792-B2 | Nitrilases, nucleic acids encoding them and methods for making and using them | BASF ENZYMES LLC (US) | 2016-04-19 | — | — | US | disclosed |
| US-9217164-B2 | Nitrilases, nucleic acids encoding them and methods for making and using them | BASF ENZYMES LLC (US) | 2015-12-22 | — | — | US | disclosed |
| US-6013830-A | CHEMICAL INTERMEDIATES FOR OXYBUTYNIN, OXYPHENCYCLIMINE, OXYPHENONIUM BROMIDE, OXYPYRRONIUM BROMIDE, AND OXYSONIUM IODIDE, FOR WHICH CYCLOHEXYLPHENYLGLYCOLIC ACID (CHPGA) IS OF SPECIAL INTEREST; STEREOSELECTIVITY | SEPRACOR INC. (US) | 2000-01-11 | — | — | US | disclosed |
| WO-1999050205-A2 | ASYMMETRIC GRIGNARD SYNTHESIS WITH CYCLIC 1,2 AMINOALCOHOLS | SEPRACOR INC. (US) | 1999-10-07 | — | — | WO | disclosed |
| US-5599820-A | Anti-tumor compounds, pharmaceutical compositions, methods for preparation thereof and for treatment | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1997-02-04 | — | — | US | disclosed |
| US-5294737-A | Hydrolysis, cyclization, condensation | THE RESEARCH FOUNDATION STATE UNIVERSITY OF NEW YORK (US) | 1994-03-15 | — | — | US | disclosed |
| US-5036107-A | Treatment of neurogenic bladder disorders | MARION MERRELL DOW INC. (US) | 1991-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120009633-A1 | NITRILASES AND METHODS FOR MAKING AND USING THEM | ASNS, DNPEP, ASPH | LMNA 2894/4885CYP2D6 692/4885CYP2C9 535/4885 |
| US-20090162906-A1 | Biocatalysts; mutant and/or chemically modified enzymes; stereoselectively hydrolyze an amino nitrile or cyanohydrin intermediate to produce the corresponding carboxylic acid; e.g. phenylglycinonitrile from benzaldehyde, potassium cyanide and ammonium chloride | PAH, ASPH, CPN1 | LMNA 1773/4885CYP2D6 935/4885CYP2C9 524/4885 |
| US-20020012974-A1 | Genetic engineered nucleic acid promoter | RNGTT, ASPH, ALKBH3 | LMNA 1933/4885CYP2D6 1936/4885CYP2C9 1461/4885 |
| US-20120009637-A1 | Nitrilases, Nucleic Acids Encoding Them and Methods For Making and Using Them | RNGTT, NSUN2, NSUN3 | LMNA 1395/4885CYP2D6 2258/4885CYP2C9 2684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.